Literature DB >> 9165066

Pancreatic procarboxypeptidases: oligomeric structures and activation processes revisited.

S Ventura1, F X Gomis-Rüth, A Puigserver, F X Avilés, J Vendrell.   

Abstract

The activation peptides of procarboxypeptidases of the A1 type act in a post-activation mechanism of control, limiting the expression of activity immediately after the limited proteolysis has occurred. This effect is due to structural complementarity between the enzymatic moiety and the released fragments, and is further enhanced by the occurrence of procarboxypeptidase A1 in oligomeric complexes of different type depending on the species studied. In those complexes, the activation segment has an important role in the stabilisation of the quaternary structure. The relationship between oligomeric structure and activation is reviewed here for two of the most extensively studied systems.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165066

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  5 in total

1.  Zebrafish cytosolic carboxypeptidases 1 and 5 are essential for embryonic development.

Authors:  Peter J Lyons; Matthew R Sapio; Lloyd D Fricker
Journal:  J Biol Chem       Date:  2013-09-10       Impact factor: 5.157

2.  Complex Formation of Human Proelastases with Procarboxypeptidases A1 and A2.

Authors:  András Szabó; Claudia Pilsak; Melinda Bence; Heiko Witt; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2016-06-29       Impact factor: 5.157

3.  Substrate specificity of human carboxypeptidase A6.

Authors:  Peter J Lyons; Lloyd D Fricker
Journal:  J Biol Chem       Date:  2010-09-20       Impact factor: 5.157

Review 4.  Structural aspects of the metzincin clan of metalloendopeptidases.

Authors:  F Xavier Gomis-Rüth
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

5.  Carboxypeptidase O is a lipid droplet-associated enzyme able to cleave both acidic and polar C-terminal amino acids.

Authors:  Linnea C Burke; Hazel O Ezeribe; Anna Y Kwon; Donnel Dockery; Peter J Lyons
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.